These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 9796989)

  • 1. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
    Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
    Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.
    Zhou XX; Ji F; Zhao JL; Cheng LF; Xu CF
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1266-75. PubMed ID: 20594254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
    Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin.
    Xu FJ; Boyer CM; Bae DS; Wu S; Greenwald M; O'Briant K; Yu YH; Mills GB; Bast RC
    Int J Cancer; 1994 Oct; 59(2):242-7. PubMed ID: 7927925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer.
    FitzGerald DJ; Bjorn MJ; Ferris RJ; Winkelhake JL; Frankel AE; Hamilton TC; Ozols RF; Willingham MC; Pastan I
    Cancer Res; 1987 Mar; 47(5):1407-10. PubMed ID: 3493065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
    Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.
    Xu F; Yu Y; Le XF; Boyer C; Mills GB; Bast RC
    Clin Cancer Res; 1999 Nov; 5(11):3653-60. PubMed ID: 10589783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody.
    Deshane J; Cabrera G; Grim JE; Siegal GP; Pike J; Alvarez RD; Curiel DT
    Gynecol Oncol; 1995 Oct; 59(1):8-14. PubMed ID: 7557620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells.
    Wiechen K; Karaaslan S; Turzynski A; Dietel M
    Br J Cancer; 1999 Nov; 81(5):790-5. PubMed ID: 10555747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human T-cell tumor growth by T101-ricin A-chain in an athymic mouse model.
    Leonard JE; Johnson DE; Shawler DL; Dillman RO
    Cancer Res; 1988 Sep; 48(17):4862-7. PubMed ID: 3261627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.
    Yu D; Liu B; Tan M; Li J; Wang SS; Hung MC
    Oncogene; 1996 Sep; 13(6):1359-65. PubMed ID: 8808711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.
    Chen X; Yeung TK; Wang Z
    Biochem Biophys Res Commun; 2000 Nov; 277(3):757-63. PubMed ID: 11062025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
    Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
    Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
    Ram TG; Hosick HL; Ethier SP
    J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
    Fulton RJ; Uhr JW; Vitetta ES
    Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
    Griffin T; Raso V
    Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
    Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
    Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction.
    Jaffrézou JP; Levade T; Thurneyssen O; Chiron M; Bordier C; Attal M; Chatelain P; Laurent G
    Cancer Res; 1992 Mar; 52(5):1352-9. PubMed ID: 1737397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity of ligand and antibody-directed ricin A-chain conjugates recognizing the epidermal growth factor receptor.
    Vollmar AM; Banker DE; Mendelsohn J; Herschman HR
    J Cell Physiol; 1987 Jun; 131(3):418-25. PubMed ID: 3496342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.